A Study to Evaluate the Efficacy and Safety of Pilocarpine Hydrochloride Ophthalmic Solution for the Treatment of Presbyopia.
- Conditions
- Health Condition 1: H524- Presbyopia
- Registration Number
- CTRI/2023/08/057127
- Lead Sponsor
- Entod Pharmaceuticals Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Adult male and female subjects, 45 to 55 years of age (both inclusive).
2. Subjects with Objective and subjective evidence of Presbyopia.
3. Subjects with subjective complaints of poor near vision that impacts the activity of daily living.
4. Subjects with photopic, high-contrast corrected distance visual acuity (CDVA) of 20/25 or better bilaterally; mesopic, high-contrast distance-corrected near visual acuity (DCNVA, measured at 40 cm) of 20/40 to 20/100; photopic, near visual acuity correctable to 20/40 or better bilaterally
5. Subjects with willingness to wear monofocal correction to achieve photopic, binocular CDVA of 20/32 or better during the study (if required).
6. Subjects who are able to understand and give voluntary, written informed consent to participate in this clinical investigation and from whom written consent has been obtained.
7. Subjects shall be willing and able to understand and comply with the requirements of the study, administer the study medication as instructed, return for the required treatment period visits, comply with therapy prohibitions, and be able to complete the study.
8. Female Subjects, of child-bearing potential practicing an acceptable method of birth control such as sexual abstinence, intrauterine device IUD, birth control pills, a double-barrier method, transdermal, injection or implants, non-hormonal or hormonal, condom plus spermicide, diaphragm plus spermicide, or vaginal spermicidal suppository; for the duration of the study as judged by the investigator(s)/study physician and agree to follow the same should be used during treatment
OR Postmenopausal for at least 1 year OR Surgically sterile (bilateral tubal ligation/bilateral oophorectomy/ hysterectomy has been performed on the Subject).
1. Documented/suspected history of hypersensitivity to the study medications or any of the ingredients of the formulation or cholinergic agonist medications.
2. Subjects with History of cataract surgery, phakic intraocular lens surgery, corneal inlay surgery, radial keratotomy, or any other intraocular surgery. However, Subjects with history of Photorefractive keratectomy (PRK) or Laser-assisted in situ keratomileusis (LASIK) with CDVA meeting inclusion criteria will be allowed to enrol.
3. Subjects with concurrent use of any topical ophthalmic medications including artificial tears, other than the study intervention during the course of the study.
4. Subjects with concurrent use of temporary or permanent punctual plugs or history of punctual cautery in one or both eyes.
5. Subjects with current enrolment in an investigational drug or device study or participation in such a study within 30 days of entry into this study.
6. Subjects with participation in a blood or plasma donation program within 30 days prior to the study intervention administration.
7. Subjects with severe dry eye disease
8. Subjects with corneal abnormalities (including Keratoconus, corneal scar, Fuch’s endothelial dystrophy, guttata or edema) in either eye that are likely to interfere the visual acuity.
9. Subjects with history of iris trauma, Adie’s tonic pupil, abnormal pupil shape in either eye, or anisocoria >1mm between pupils under mesopic conditions at the screening visit.
10. Subjects with all grades of cataract.
11. Subjects with diagnosis of Glaucoma or ocular Hypertension.
12. Subjects with Bifocal or multifocal spectacles or contact lenses for habitual correction.
13. Females who are pregnant, nursing or planning a pregnancy during the study.
14. Subjects with history of chronic, recurrent, or current severe inflammatory eye disease (i.e., scleritis, uveitis, herpes keratitis) in either eye.
15. Subjects with documented history of ocular trauma = 6 months before the study.
16. Subjects with documented history of clinically significant or progressive retinal disease (e.g., retinal degeneration, diabetic retinopathy, retinal detachment) in either eye.
17. Subjects with one eye.
18. Subjects with severe illness or other condition that would make the patient unsuitable for the study, as per investigator discretion.
19. Subjects with active or prior severe, unstable, or uncontrolled cardiovascular, cerebrovascular, hepatic, or renal disease.
20. Subjects with use of topical ophthalmic corticosteroid within two weeks prior to baseline visit.
21. Subjects with use of intraocular corticosteroid implant at any time prior to baseline visit.
22. Subjects with clinically significant laboratory abnormalities at the time of screening.
23. Currently taking prohibited concomitant medications(s) listed and inability/unwillingness to discontinue them for the entire study period.
24. Subjects who are known seropositive cases of HIV, Hepatitis B or Hepatitis C.
25. Subjects who have a recent history or who are currently known to abuse alcohol or drugs.
26. Suspected inability or unwillingness to comply with the protocol or other study procedures.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method